HER-2 amplification

HER2 (CRC, Gastric and breast- Amplification; NSCLC -oncogenic mutations) *without looking at other answers or @OncoKB (@CDebyaniPhD)

In this #ASCO23 interview, @DrShubhamPant of @MDAndersonNews discusses the results of the #HERIZON-BTC-01 trial of #zanidatamab in previously treated #HER2-amplified #biliary tract #cancers. Listen to the conversation here! https://t.co/9j8Xvm7ds3 (@OncData)

WATCH: @kanwal_raghav, of @MDAndersonNews, discusses the rationale behind the phase 2 DESTINY-CRC02 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with metastatic colorectal cancer with HER2 amplification or overexpression. #crcsm https://t.co/ZqGpvZQLhy (@OncLive)

Hot off the press from @ASCO #TAPUR Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study https://t.co/ilNcPYdV8U (@rschilsky)

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine. @DrShubhamPant @MDAndersonNews #ASCO23 #oncology https://t.co/hCLD2Q81YP (@OncLive)

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine. @DrShubhamPant @MDAndersonNews #ASCO23 #oncology https://t.co/AI03UpN2Va (@OncLive)

Zanidatamab Elicits Responses in HER2-amplified Advanced Biliary Tract Cancer @DrShubhamPant @MDAndersonNews @ASCO #ASCO23 #oncology https://t.co/EGmjceI4ky (@OncLive)

🆕HERIZON-BTC-01 study: Zanidatamab in previously-treated 🎯#HER2‑amplified biliary tract cancer (BTC) @DrShubhamPant Again gallbladder ca >1/2 of these cases. #ASCO23 @OncoAlert HER2➕in cholangiocarcinoma needs approvals. @NCCN only trastuzumab/pertuzumab. No @FDAOncology. (@pashtoonkasi)

🔥HERIZON-BTC-01: Zanidatamab in HER2‑amplified biliary tract cancer #ASCO23 🔎🌎phs-II, 87 pts 👉cORR 41%, DOR 12.9 mo 👉mPFS 5.5 👉no grade 4 TRAEs ✅Durable responses with manageable safety profile -> very promising 💊 option @myESMO @OncoAlert @EASLedu @curecc #livertwitter (@ArndtVogel)

🔥 SGNTUC-019: Tucatinib & trastuzumab for HER2+ biliary tract cancer #ASCO23 🔎phs-II, 30 pts, Her2 overexpression/amplification 👉ORR: 46.7%, DoR 6.0mo, DCR 76.7% 👉mPFS 5.5 mo, 12-mo OS rate 53.8% ✅Supports TUC/Tras as CTx-free💊option @myESMO @OncoAlert @EASLedu @curecc… https://t.co/s4WLttkRA2 (@ArndtVogel)

🔥Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON- BTC-01) @TheLancetOncol https://t.co/z9SLPXMe7g ✳️Phase 2 study just presented at #ASCO23 ✅ Her2 is a relevant🎯💊in BTC @myESMO @EASLedu #livertwitter @curecc @ILCAnews https://t.co/5tJeTzUfvE (@ArndtVogel)

@DrShubhamPant @giconnectInfo expert will present today at #ASCO23: Results from the pivotal phase2b HERIZON-BTC-01 study: #zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC) https://t.co/4m2RjwLKFe 17:09 GMT-5, Arie Crown Theater #MedEd (@giconnectInfo)

Enhertu made by @AstraZeneca who not yet involved in DETERMINE. There is an arm for HER2 mutated/ amplified using trastuzumab/pertuzumab. As Enhertu approved FDA should be evaluated by @MHRAgovuk and @NICEComms through project orbis. Need to ensure Her2 on test directory #lcsm (@AlastairGreyst2)

I expect an agnostic approval based on the two data sets. It is interesting to see in the #HERALD trial the two patients with NSCLC not responding (albeit only 2), in line with what we know about the activity of #tdxd in ERBB2 mutant NSCLC but not much in the amplified tumors. (@AnisToumeh)

The @myESMO preceptorship on colorectal cancer is going on. @grikamartinelli is now covering treatment for BRAF mutant and HER2 amplified tumors (@AndresC27622123)

How does oncogene (e.g. ERBB2) amplifications occur during the development of breast cancer? Interesting mechanistic explanation described in this @Nature paper, highlighting a key role for estrogen exposure. https://t.co/a5WAFqc4uy (@PTarantinoMD)

Amazing molecular tumor #MTB board in #GUcsm with @FoundationATCG Two ✌️ interesting cases ➡️ Penile carcinoma 🧬high TMB & BRCA & HER2 amplification....What to do?? By @fedelosco ➡ Prostate cancer 🧬HRR mutation in MRE11A. Does iPARP work?. By me @fundacion_FUCA @IAF_Fleming (@Martin_AngelMD)

👉✅ IT OUT❗️Our publication👇showing ERBB2 amplification in ctDNA (for HER2+ gastric cancer) predicts response 👇. Trials now at @RutgersCancer @RWJBarnabas (@HH_Oncodr)

HER2-amplified #breastcancer in early and metastatic setting with @curijoey @aaoncoclinica @myESMO #esmolatinamericasummit #BuenosAires (@TeresaSAmaral)

Case 1 represents the most impressive effort, multi-institutional in nature, combining targeted therapy, #immunotherapy & radiation in a patient with widely metastatic Her-2 amplified #PancreaticCancer. https://t.co/xogErL1N0z #OpenAccess in @JCOPO_ASCO (@Aiims1742)

#HER2 amplification is an effective therapeutic target in breast, gastric, and lung cancer 🧬 Explore the gene as a target, biomarker, and more with Sabina Berezowska, alongside, Zsuzsanna Varga, @FlorianLordick & @hausruck1. ⏰ Wed 19th April at 5PM CEST Tune in for free ⬇️ (@OncoViews)

Just published! Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study https://t.co/GeWgWqTgV7 (@rschilsky)

#GDUGI23 Great talk by Dr. John Strickler on Emerging treatment strategies for HER2+ mCRC: Molecular profiling and targeted therapies #CRCSM #ERBB2 Very nice discussion: NGS companies reporting HER2 amplification, please report copy numbers @FoundationATCG @carisls @TempusLabs (@manjuggm)

Congrats ⁦@sarahleemdmba⁩ #sgo2023 Simultaneous #Her2 overexpression and #CCNE amplification have worse outcome in black patients with #endometrial #cancer ⁦@SGO_org⁩ ⁦@GOG⁩ ⁦@acog⁩ ⁦@IGCSociety⁩ ⁦@Perlmutter_CC⁩ @gyncsm ⁦@SHAREing⁩ (@BPothuri)

Excellent discussion of all the options for Her2 amplified Breast Cancer by Dr. Nagender Sharma, Medical Oncologist at Delhi. Venue: TMH Varanasi Conference at Hotel Clarks @DrVijayPatil11 @Bipinesh @dranuj16 @myESMO @ASCO @sujithonco (@drakhilkapoor1)

A 3: ✳️ For MSS CRC pts who do not have actionable alterations; 📌HER2 amplification ‼️ 📌BRAF V600E‼️ 📌KRAS G12C ‼️ 📌POLE/POLD1‼️ or aren't eligible for trials, Lonsurf +Bev: good alternative. Bev needs to be added to Lonsurf regardless of prior Bev ‼️ #CRCTrialsChat #CRCSM (@IbrahimSahinMD1)

Selecting patients with #ColorectalCancer who have HER2➕➕➕is similar to the traditional paradigm. IHC➕➕➕ IHC➕➕&FISH ERBB2 Amplification Not mutation. We presented data @ASCO on concordance of breast & gastric algorithms for HER2; 💯% concordance. Rectal/LEFT-Colon⬆️⬆️. (@pashtoonkasi)

👇Nice ASCO abstract!In our small numbers- they tend to be basal-like, Ive had a patient PD on pseudoadjuvant mFFX but respond to GnP with NED- tumour was also HER2 amplified! (havent need to target yet) I would favour GnP if a sarcomatoid PC https://t.co/lpabcpIWSy (@graokane)

So let's add this up for upper gi cancers: 38% Claudin 18.2 20% HER2 amplified ~3% MSI-H ~ 2-3% BRCA1/2 1% RTK fusion ➕️ What am I missing❓️ Point is - >50% of upper gi cancers have an actionable biomarker TEST, TEST, TEST, TEST, TEST (@MPishvaian)

Another line of chemo-free tx (tucatinib+Traustuzumab) for mCRC RAS WT patients with HER2/ERBB2 amplification Congrats to @SeagenGlobal. Listen to Dr. John Strickler here https://t.co/6W4vkxXVgf Don't forget to check HER2 status in rectal cancer #CRCSM (@manjuggm)

#HER2low #PathTwitter #BreastPath #SABCS22 Its a prognostic and predictive assay in early stage HER2 positive breast cancer. It takes into account clinical features and expression of "4Gene signatures" ie immune, proliferation, differentiation and HER 2 amplification. (@israhkhan)

Behaved like a typical HER2 and EGFR co-amplification mNSCLC case. Usually the disease gets resistant by 6months as was seen in your case sir. (@saadvikdr)

⭐️🧑‍🔬Clinical Trial: Zanidatamab is a bispecific monoclonal antibody targeting two non-overlapping domains of HER2. Evaluation of its safety and anti-tumour activity in solid tumours with HER2 expression or amplification here; https://t.co/lmhFb9W2ej @DrShubhamPant @kanwal_raghav (@alfaro_kristin)

⭐️🧑‍🔬Clinical Trial: Zanidatamab is a bispecific monoclonal antibody targeting two non-overlapping domains of HER2. Evaluation of its safety and anti-tumour activity in solid tumours with HER2 expression or amplification here; https://t.co/uqacQQpASH DrShubhamPant kanwal_raghav (@skopetz)

🔥Zymeworks announces pos. data in the HERIZON-BTC-01 trial of Zanidatamab🔥 https://t.co/Fnw5ORCifN ✅100pts, phs-IIb, bi-specific AB 👉HER2-amplified & expressing #biliarytractcancer 💪ORR 41%, DoR 12.9 mo 😀expanding options for🎯💊 @myESMO @OncoAlert @EASLedu #livertwitter (@ArndtVogel)

Positive results with #zanidatamab in patients with previously treated #HER2-amplified and expressing #biliarytractcancers #BTCs #cholangiocarcinoma #CCA ORR 41.3%, mDOR 12.9 months. Waiting for approval. Another treatment option for our patients! (@LorenzaRimassa)

🚨🚨Top line Results of Global Study of Zanidatamab (Bispecific targeting HER2) in patients after first line therapy for Her2 Amplified Biliary Tract Cancers ➡️cORR 41.3% ➡️Median DOR 12.9 months Thank you 🙏🙏 to patients, co-investigators ➡️Full results to be presented 2023 (@DrShubhamPant)

Some predictive factors allow for predicting the response to the treatment. There are 3 predictive factors of breast cancer cells, such as ER (estrogen receptor) PR (progesterone receptor) HER2/Neu gene amplification (@sdmedicwind)

Podcast, *Learning about New Her2 LOW* w/ Dr. Hicks #breastpath and @maryam_lustberg #breastoncology. Review of HER2 amplification, overexpression; and ideas for #pathologists on what to do w/ HER2 ihc 1+ results while awaiting guidelines update. https://t.co/1i3MAhgZvj (@JLRudzinskiMD)

.@CareFirst #BlueCross #BlueShield FEP does not provide care consistent with the @NCCN guidelines by denying approval of trastuzumab deruxtecan for a patient with metastatic colon cancer with #HER2 amplification following progression on chemo #colorectalcancer #crcsm #medtwitter (@benweinbergmd)

🔥Trastuzumab + FOLFOX for HER2+ biliary tract cancer🔥 @LancetGastroHep https://t.co/olurYdJedK 👉more options of 🎯💊in #CCA 👉MyPathway, HERB, ZW25, SUMMIT & now KCSG-HB19–14 ✅#CCA: Her2 mutations, amplifications & overexpression❗️ @myESMO @OncoAlert @EASLnews (@ArndtVogel)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic #colorectalcancer: the #phaseII HERACLES-B trial @OncoAlert @myESMO @cczielinski @PaoloBossi6 https://t.co/yUmwI6ofKR (@ESMO_Open)